Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Prognostic Markers in Cardiac Non-Hodgkin Lymphoma: A Retrospective Review

Max J Gordon, MD, Alexey V. Danilov, MD PhD

Blood (2015) 126 (23): 5007.

https://doi.org/10.1182/blood.V126.23.5007.5007

Published: 2015

Journal Articles

PD-L1 and PD-L2 Protect The Heart In a T-Cell Receptor Transgenic Model Of Graft-Versus Host Disease

Kathryn W Juchem, PhD, Britt Anderson, PhD, Cuiling Zhang, Arlene Sharpe, MD, PhD, Jennifer McNiff, MD, Anthony Demetris, MD, Mark J Shlomchik, MD, PhD, Warren D Shlomchik, MD

Blood (2013) 122 (21): 4479.

https://doi.org/10.1182/blood.V122.21.4479.4479

Published: 2013

Journal Articles

Utility Of Pre-Chemotherapy Echocardiograms

John Allen Steuter, MD/Cardiology Fellow, Philip Bierman, MD, R. Gregory Bociek, MD, Martin Bast, BS

Blood (2013) 122 (21): 2950.

https://doi.org/10.1182/blood.V122.21.2950.2950

Published: 2013

Journal Articles

Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).

Angela Dispenzieri, MD, Lijung Zhang, M.S., Rafael Fonseca, M.D., David H. Vesole, M.D., Ph.D., Philip R. Greipp, M.D.

Blood (2006) 108 (11): 3527.

https://doi.org/10.1182/blood.V108.11.3527.3527

Published: 2006

Journal Articles

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Angela Dispenzieri, MD, Emily Blood, MS, David Vesole, MD, Rafael Fonseca, MD, Natalie Callander, MD, Philip R. Greipp, MD

Blood (2005) 106 (11): 2546.

https://doi.org/10.1182/blood.V106.11.2546.2546

Published: 2005

Journal Articles

Lentivirus-Mediated Platelet-Specific Gene Therapy of Hemophilia A.

Qizhen Shi, D.A. Wilcox, S.A. Fahs, J. Fang, B.D. Johnson, H. Weiler, R.R. Montgomery

Blood (2004) 104 (11): 2974.

https://doi.org/10.1182/blood.V104.11.2974.2974

Published: 2004

Journal Articles

Identification of New Markers for the Detection of Minimal Residual Disease in AML by Gene Expression Profiling and Real Time PCR.

Daniel Steinbach, MD, Alexander Schramm, MD, Angelika Eggert, MD, Susann Wittig, Felix Zintl, MD, Bernd Gruhn, MD

Blood (2004) 104 (11): 2008.

https://doi.org/10.1182/blood.V104.11.2008.2008

Published: 2004

NARROW

Prognostic Markers in Cardiac Non-Hodgkin Lymphoma: A Retrospective Review

PD-L1 and PD-L2 Protect The Heart In a T-Cell Receptor Transgenic Model Of Graft-Versus Host Disease

Utility Of Pre-Chemotherapy Echocardiograms

Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Lentivirus-Mediated Platelet-Specific Gene Therapy of Hemophilia A.

Identification of New Markers for the Detection of Minimal Residual Disease in AML by Gene Expression Profiling and Real Time PCR.

Email alerts

ASH Publications

American Society of Hematology

Prognostic Markers in Cardiac Non-Hodgkin Lymphoma: A Retrospective Review

PD-L1 and PD-L2 Protect The Heart In a T-Cell Receptor Transgenic Model Of Graft-Versus Host Disease

Utility Of Pre-Chemotherapy Echocardiograms

Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Lentivirus-Mediated Platelet-Specific Gene Therapy of Hemophilia A.

Identification of New Markers for the Detection of Minimal Residual Disease in AML by Gene Expression Profiling and Real Time PCR.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only